Nkarta NKTX Stock
Nkarta Price Chart
Nkarta NKTX Financial and Trading Overview
| Nkarta stock price | 8.74 USD |
| Previous Close | 4.41 USD |
| Open | 4.4 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 4.35 - 4.99 USD |
| 52 Week Range | 3.12 - 18.48 USD |
| Volume | 634.72K USD |
| Avg. Volume | 341.84K USD |
| Market Cap | 242.23M USD |
| Beta (5Y Monthly) | 0.169276 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.43 USD |
NKTX Valuation Measures
| Enterprise Value | -16243968 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8131868 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.6986591 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.131 |
Trading Information
Nkarta Stock Price History
| Beta (5Y Monthly) | 0.169276 |
| 52-Week Change | -59.59% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 18.48 USD |
| 52 Week Low | 3.12 USD |
| 50-Day Moving Average | 4.55 USD |
| 200-Day Moving Average | 7.38 USD |
NKTX Share Statistics
| Avg. Volume (3 month) | 341.84K USD |
| Avg. Daily Volume (10-Days) | 230.46K USD |
| Shares Outstanding | 48.93M |
| Float | 29.93M |
| Short Ratio | 11.36 |
| % Held by Insiders | 7.12% |
| % Held by Institutions | 88.40% |
| Shares Short | 3.22M |
| Short % of Float | 9.37% |
| Short % of Shares Outstanding | 6.57% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.79% |
| Return on Equity (ttm) | -41.24% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -124346000 USD |
| Net Income Avi to Common (ttm) | -118665000 USD |
| Diluted EPS (ttm) | -2.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 323.34M USD |
| Total Cash Per Share (mrq) | 6.61 USD |
| Total Debt (mrq) | 91.29M USD |
| Total Debt/Equity (mrq) | 26.34 USD |
| Current Ratio (mrq) | 12.786 |
| Book Value Per Share (mrq) | 7.085 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -59500000 USD |
| Levered Free Cash Flow (ttm) | -100010248 USD |
Profile of Nkarta
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 6000 Shoreline Court |
| ZIP | 94080 |
| Phone | 925 407 1049 |
| Website | https://www.nkartatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 165 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Q&A For Nkarta Stock
What is a current NKTX stock price?
Nkarta NKTX stock price today per share is 8.74 USD.
How to purchase Nkarta stock?
You can buy NKTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nkarta?
The stock symbol or ticker of Nkarta is NKTX.
Which industry does the Nkarta company belong to?
The Nkarta industry is Biotechnology.
How many shares does Nkarta have in circulation?
The max supply of Nkarta shares is 70.43M.
What is Nkarta Price to Earnings Ratio (PE Ratio)?
Nkarta PE Ratio is now.
What was Nkarta earnings per share over the trailing 12 months (TTM)?
Nkarta EPS is -2.4 USD over the trailing 12 months.
Which sector does the Nkarta company belong to?
The Nkarta sector is Healthcare.
Nkarta NKTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}